1 Min Read
ZURICH (Reuters) - Johnson & Johnson (JNJ.N) said Friday's approval of its proposed acquisition of Swiss biotech company Actelion (ATLN.S) by the European Commission meant all regulatory approvals required to complete the $30 billion deal have been received.
The U.S. company said it expects settlement of the all-cash public tender offer by its Swiss subsidiary, Janssen Holding, on June 16.
EU antitrust regulators approved on Friday Johnson & Johnson's planned purchase of Actelion subject to conditions intended to ensure clinical development of insomnia drugs were unaffected.
Reporting by John Revill; editing by Brenna Hughes Neghaiwi